Geode Capital Management LLC recently announced the acquisition of new stake in Nautilus Biotechnology Inc. (NASDAQ:NAUT). The institutional investor has increased its shareholding in the Healthcare company by 0.45% to 0.96 million shares with purchase of 4290.0 shares. This fresh investment now brings its stake to 0.77% valued currently at $1.72 million. In addition, SSgA Funds Management, Inc. raised its holdings by 72142.0 to 0.65 million shares.
With over 0.25 million Nautilus Biotechnology Inc. (NAUT) shares trading Friday and a closing price of $2.06 on the day, the dollar volume was approximately $0.52 million. The shares have shown a negative half year performance of -24.54% and its price on 01/13/23 gained nearly 0.98%. Currently, there are 124.65M common shares owned by the public and among those 90.46M shares have been available to trade.
The analysts have set the share’s price value over the next 12 months at a high of $7.00 and a low of $2.00. The average price target is 58.8% above its recent price level and a downside to the estimated low will see the stock lose -3.0% over that period. But an upside of 70.57% will see the stock hit the forecast high price target while median target price for the stock is $6.00.
Insiders at the company have transacted a total of 15 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 15 of these insider trades were purchases, accounting for 313,100 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Nautilus Biotechnology Inc. are Vanguard Total Stock Market Index, iShares Russell 2000 ETF, and Vanguard Extended Market Index Fu. Vanguard Total Stock Market Index owns 1.14 million shares of the company’s stock, all valued at over $2.05 million. iShares Russell 2000 ETF sold 9577.0 shares to see its total holdings shrink to 0.92 million shares valued at over $1.65 million and representing 0.74% of the shares outstanding. Vanguard Extended Market Index Fu now owns shares totaling to 0.53% of the shares outstanding.
Shares of Nautilus Biotechnology Inc. (NASDAQ: NAUT) opened at $2.025, down -$0.02 from a prior closing price of $2.04. However, the script later moved the day high at 2.0800, up 0.98%. The company’s stock has a 5-day price change of 15.73% and 0.98% over the past three months. NAUT shares are trading 14.44% year to date (YTD), with the 12-month market performance down to -56.36% lower. It has a 12-month low price of $1.50 and touched a high of $5.07 over the same period. NAUT has an average intraday trading volume of 154.01K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 17.41%, 12.05%, and -23.82% respectively.
Institutional ownership of Nautilus Biotechnology Inc. (NASDAQ: NAUT) shares accounts for 45.50% of the company’s 124.65M shares outstanding. Mutual fund holders own 42.95%, while other institutional holders and individual stakeholders account for 5.20% and 17.27% respectively.
It has a market capitalization of $254.41M. The earnings-per-share (ttm) stands at -$0.49. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.34% over the week and 8.90% over the month.
Analysts forecast that Nautilus Biotechnology Inc. (NAUT) will achieve an EPS of -$0.15 for the current quarter, -$0.16 for the next quarter and -$0.84 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.16 while analysts give the company a high EPS estimate of -$0.14. Comparatively, EPS for the current quarter was -$0.12 a year ago. Earnings per share for the fiscal year are expected to decrease by -221.60%, and -58.80% over the next financial year.
Looking at the support for the NAUT, a number of firms have released research notes about the stock. Morgan Stanley stated their Equal-Weight rating for the stock in a research note on January 06, 2022, with the firm’s price target at $8. Goldman was of a view on August 04, 2021 that the stock is Neutral, while Jefferies gave the stock Buy rating on July 13, 2021, issuing a price target of $13.